2018
DOI: 10.1038/d41586-018-05765-y
|View full text |Cite
|
Sign up to set email alerts
|

Drug candidate and target for leishmaniasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
16
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4
3
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(17 citation statements)
references
References 10 publications
1
16
0
Order By: Relevance
“…Evaluating the predicted GO terms for those 68 selected proteins, it was noticeable that we identified proteins related to functions already well-described and used by the pharmaceutical industry, such as those with kinase activity (Supplementary Material 1), a class of proteins that has already been used as drug targets for inflammatory, autoimmune diseases and cancer (Cohen, 2009;Cohen and Alessi, 2013;Patterson et al, 2014;Bhullar et al, 2018). This finding is consistent with the literature since that class of proteins has also been indicated as possible drug targets for the treatment of leishmaniasis caused by L. donovani and Leishmania mexicana (Ali et al, 2012;Rachidi et al, 2014;Catta-Preta and Mottram, 2018;Raj et al, 2019). The potential of neutralizing proteins of that class has also been demonstrated by the use of the kinase inhibitor Trametinib for amastigotes and promastigotes of L. braziliensis and L infantum (Borba et al, 2019).…”
Section: Discussionsupporting
confidence: 83%
“…Evaluating the predicted GO terms for those 68 selected proteins, it was noticeable that we identified proteins related to functions already well-described and used by the pharmaceutical industry, such as those with kinase activity (Supplementary Material 1), a class of proteins that has already been used as drug targets for inflammatory, autoimmune diseases and cancer (Cohen, 2009;Cohen and Alessi, 2013;Patterson et al, 2014;Bhullar et al, 2018). This finding is consistent with the literature since that class of proteins has also been indicated as possible drug targets for the treatment of leishmaniasis caused by L. donovani and Leishmania mexicana (Ali et al, 2012;Rachidi et al, 2014;Catta-Preta and Mottram, 2018;Raj et al, 2019). The potential of neutralizing proteins of that class has also been demonstrated by the use of the kinase inhibitor Trametinib for amastigotes and promastigotes of L. braziliensis and L infantum (Borba et al, 2019).…”
Section: Discussionsupporting
confidence: 83%
“…Leishmania parasites invade, develop and replicate inside the host Mononuclear Phagocyte System (MPS), attacking macrophages and dendritic cells. [24][25][26] Incubation time of Leishmania parasite from promastigote to amastigote takes between two and three months, time range when the host immune system response activates and leads to an favorable or unfavorable outcome. 25 The parasite cycle begins with the bite of an infected female sandfly, carrier of promastigote Leishmania parasites in a meta-cyclic state (see Fig.…”
Section: Leishmania Life Cycle and Host Immune Responsementioning
confidence: 99%
“…Leishmania parasites invade, develop and replicate inside the host Mononuclear Phagocyte System (MPS), attacking macrophages and dendritic cells. [21][22][23] Incubation time of Leishmania parasite from promastigote to amastigote takes between two and three months, time range when the host immune system response activates and can be favorable or unfavorable. 22 The parasite cycle begins with the bite of an infected female sandfly, carrier of promastigote Leishmania parasites in a meta-cyclic state (see Fig.…”
Section: Leishmania Life Cycle and Host Immune Responsementioning
confidence: 99%